How does Dexcom, Inc. turn continuous glucose monitors into recurring revenue and clinical value?
Dexcom, Inc. sells CGM sensors and transmitters plus software that streams glucose data to patients and clinicians, shifting care from fingersticks to continuous monitoring. In 2025 Dexcom reported $3.6 billion in product revenue, underlining a durable razor-and-blade model and growing pharmacy distribution.
Dexcom, Inc. locks customers via sensor subscriptions and data ecosystems; sensors wear out, creating steady replacement revenue and strong gross margins-pharmacy channels raised refill convenience in 2025. See product detail: DexCom SWOT Analysis
What Does DexCom Actually Sell?
Dexcom, Inc. sells an integrated continuous glucose monitoring platform: prescription-grade sensors and transmitters, OTC consumer monitors, and ecosystem software that removes fingersticks and warns of dangerous glucose swings.
Core product tiers and devices
Dexcom offers prescription sensors and transmitters (flagship Dexcom G7 and G7 15 Day system), an OTC consumer CGM called Stelo for non-insulin users, and receivers/patches. The G7 15 Day reports glucose every few minutes with a reported MARD of 8.0 percent.
Who it serves
Patients with Type 1 and insulin-using Type 2 diabetes, clinicians, and wellness consumers seeking preventive monitoring. Payers and health systems are targeted for population management and cost reduction programs.
Software, services, and integrations
Dexcom sells ecosystem software: Dexcom Clarity for clinician analytics, Dexcom Follow for caregivers, the Dexcom mobile app for live readings, plus FDA-cleared features like Smart Basal for optimized insulin dosing and integrations with insulin pumps and digital health partners.
Value delivered to customers
Customers get near-real-time glucose trends, predictive alerts to prevent hypoglycemia and hyperglycemia, and elimination of routine fingerstick tests; clinically, CGM use lowers time below range and improves time in range (TIR).
Why customers choose Dexcom
High accuracy (G7 MARD 8.0%), frequent readings, broad integrations (pumps, apps), and an end-to-end platform make Dexcom attractive and stickier for clinicians and patients alike.
Business and market context
Revenue drivers include recurring sensor and transmitter sales, OTC expansion with Stelo, and software/partnership monetization; for strategic direction see Where DexCom Company Is Going.
DexCom SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Does DexCom Run Day to Day?
Dexcom, Inc. runs day-to-day by combining precision biosensor manufacturing with a healthcare distribution network and device integrations, producing millions of disposable continuous glucose monitoring sensors annually to support patients and partners.
Operating model: precision manufacturing meets healthcare logistics
Dexcom corporate centers on high-volume sensor production, quality control, regulatory compliance, and a sales organization that shifts patients from DME to pharmacy and direct channels for better adherence.
Product delivery: prescriptions, pharmacy, and direct-to-consumer
Prescription products like Dexcom G7 move through pharmacy and DME routes; consumer-focused offerings such as Stelo use direct channels including Amazon to simplify access and refills.
Production and sourcing: US plants plus Malaysia contract manufacturing
Daily ops mix in-house US manufacturing with contract manufacturing in Malaysia to hit scale - the firm reported manufacturing millions of sensors for fiscal 2025 to meet global demand and manage inventory buffers.
Sales channels: pharmacy pivot and digital platforms
Dexcom shifted from Durable Medical Equipment providers toward pharmacy fulfillment to reduce refill friction; the Dexcom mobile app and online stores support subscriptions and reorders.
Key systems and partnerships: integrations and data platforms
Dexcom supports integrations with over 90 partners, feeding sensor glucose data into AID systems (Omnipod 5, Beta Bionics iLet) and analytics tools like Dexcom Clarity to power therapy and clinical decisions.
What makes it work: scale, regulatory rigor, and interoperability
The model relies on reproducible sensor manufacturing, FDA-clearance processes, pharmacy distribution economics, and broad device interoperability so sensors become the required data feed for closed-loop therapies.
Daily mechanics: from production lines to app-driven patient care
Operationally, Dexcom synchronizes manufacturing throughput, regulatory lot release, channel fulfillment (pharmacy, DME, direct), and continuous software/device integrations so sensors reliably deliver glucose data to phones, receivers, and insulin pumps every day.
- Core operating model: high-volume sensor manufacturing plus regulatory and quality control workflows
- Product delivery: prescriptions filled via pharmacy and direct-to-consumer options for faster refills and adherence
- Main support: partnerships with 90+ device vendors and analytics (Dexcom Clarity) plus US and Malaysia manufacturing footprint
- Efficiency driver: standardized production, pharmacy distribution economics, and mandatory interoperability for closed-loop systems
See operational context and corporate purpose in this company article: What DexCom Company Stands For
DexCom PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
How Does Money Come In at DexCom?
Dexcom, Inc. earns most revenue from recurring disposable sensors under a razor-and-blades model, with hardware as the entry point and sensors sold frequently. Primary streams are insurance reimbursement, pharmacy copays, and cash retail for Stelo devices.
Consumable Sensors Drive Revenue
Recurring disposable sensors are the main revenue source: in late 2025 over 97 percent of Dexcom, Inc. revenue came from sensors, making continuous glucose monitoring consumables the core of the business model.
Insurance, Pharmacy, and Cash Channels
Revenue is collected via Medicare and private PBMs (insurance reimbursement), pharmacy benefit copays, and direct cash-pay retail for Stelo priced between $89 and $99.
Pricing and Monetization Model
Dexcom monetizes through one-time hardware sales (receivers/transmitters) plus high-frequency consumable sensor sales; insurers and PBMs cover most recurring purchases while some users pay retail for Stelo.
Repeat Demand and Volume Scale Revenue
Repeat sensor replacement frequency and growing user base for Dexcom G6 and Dexcom G7 products drive scale; volume and mix improvements support margin expansion.
How Money Comes In
Dexcom turns device adoption into recurring revenue by selling sensors on a frequent replacement cadence, collecting payments mainly through insurance and pharmacy channels while some retail Stelo sales supplement cash flow.
- Sensors (consumables) - > 97 percent of late-2025 revenue
- Insurance reimbursement and PBMs - primary payment route
- Pricing model - hardware entry plus recurring sensor purchases; Stelo retail $89-$99
- Top driver - repeat demand and scale; 2025 revenue $4.662 billion, guidance 2026 $5.16-$5.25 billion
For operational detail on distribution and sales channels, see How DexCom Company Sells and Dexcom corporate filings reporting a 2025 non-GAAP operating margin of 20.8 percent with projected expansion to 22-23 percent in 2026.
DexCom SOAR Analysis
- Complete SOAR Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Makes DexCom's Model Strong or Fragile?
Dexcom, Inc.'s model is strong because clinical accuracy and ecosystem integrations create recurring, subscription-like revenue, but it is fragile due to pricing pressure, regulatory quality risks, and consumer volatility as it shifts toward OTC metabolic-health products.
Clinical accuracy and ecosystem lock-in
Dexcom corporate benefits from a market-leading 8.0 percent MARD accuracy for Dexcom G6 (benchmark for continuous glucose monitoring), which makes sensors essential for insulin users and supports integrations with insulin pumps and digital insulin titration. This clinical edge turns purchases into predictable, recurring sensor sales rather than one-time buys.
Scale, regulatory approvals, and platform software
Dexcom's installed base, Dexcom G6 and emerging Dexcom G7 adoption, plus software like Dexcom mobile app and Dexcom Clarity, create data-driven stickiness and payer familiarity that eases reimbursement and clinician adoption. Partnerships with pump makers amplify network effects and raise switching costs.
Concentration, manufacturing, and regulatory constraints
Revenue depends on recurring sensor replacement and payer reimbursement concentration; manufacturing quality is critical after a March 2025 FDA warning letter on manufacturing control issues, showing license risk if quality systems fail. International pricing pressure from higher-volume competitors compresses margins.
Durability in 2025/2026
In 2025 Dexcom, Inc. looks partly resilient but exposed: clinical superiority and platform expansion into the US non-insulin Type 2 address growth, while Abbott-led price competition, OTC Stelo consumer volatility, and regulatory manufacturing risk create downside. The model can hold if quality and pricing mix stabilize.
Net assessment of what strengthens or weakens the model
Dexcom's strength is clinical accuracy and ecosystem integration that convert users into recurring revenue; its fragility stems from pricing competition, manufacturing/regulatory exposure, and retail volatility as it expands beyond prescription users.
- Market-leading clinical accuracy (8.0 percent MARD) drives stickiness
- Integrated assets: Dexcom G6/G7, Dexcom mobile app, Dexcom Clarity, and pump partnerships
- Key dependency: flawless manufacturing and regulatory compliance after the March 2025 FDA warning letter
- The model is cautiously resilient but exposed to price wars and OTC consumer churn
For competitive context and peers, see Who DexCom Company Competes With
DexCom VRIO Analysis
- Covers VRIO Analysis in Details
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
Frequently Asked Questions
DexCom sells an integrated continuous glucose monitoring platform. That includes prescription sensors and transmitters like Dexcom G7 and G7 15 Day, the OTC Stelo monitor, receivers and patches, plus software such as Dexcom Clarity, Dexcom Follow, and the Dexcom mobile app.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.